An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Tirapazamine (Primary)
- Indications Colorectal cancer; Liver metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Teclison
- 22 Nov 2024 Planned primary completion date changed from 30 Oct 2025 to 30 Dec 2025.
- 18 Sep 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 18 Sep 2023 Planned primary completion date changed from 30 Oct 2024 to 30 Oct 2025.